{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:13:14Z","timestamp":1793074394858,"version":"4.5.0"},"reference-count":95,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,7,3]]},"DOI":"10.1080\/13543776.2022.2067478","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T15:42:06Z","timestamp":1650296526000},"page":"731-742","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":46,"title":["ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-0722","authenticated-orcid":false,"given":"Carlotta","family":"Granchi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1021\/bi300611s"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)90705-2"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164097"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)40033-1"},{"issue":"5","key":"cit0005","first-page":"391","volume":"45","author":"MacDonald MJ","year":"2013","journal-title":"Horm Metab Res"},{"key":"cit0006","unstructured":"Vzw VIB, Universiteit Gent. Crystal structure of ATP citrate lyase and uses thereof. WO2020182615. 2020."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1095-5"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-019-0351-6"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1094-6"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.580167"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00189-14"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.4161\/auto.36413"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuaa061"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.09.001"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2019.101006"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.09.004"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-4112"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.12.010"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000390"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01143"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.777273"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.011338"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.09.008"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208773"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202107223"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0567"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121971"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0098"},{"issue":"5","key":"cit0030","first-page":"7855","volume":"8","author":"Qian X","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.04.024"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642229"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16235"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2020.05.010"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31249"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153076"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1359"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1391-9"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12194-6"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22774"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.008708"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.02.006"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112962"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123054"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20141-z"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006685"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)69735-2"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2009.0222"},{"key":"cit0049","unstructured":"Nimbus Artemis, Inc. ACLY inhibitors and uses thereof. WO2020097408. 2020."},{"key":"cit0050","unstructured":"Smith-Kline Beecham PLC. Phenylderivative as inhibitors of ATP citrate lyase. WO9322304. 1993."},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1021\/jm980091z"},{"key":"cit0052","unstructured":"Smith-Kline Beecham PLC. Phenylderivate as inhibitors of ATP citrate lyase. US5447954. 1995."},{"key":"cit0053","unstructured":"The Trustees of the University of Pennsylvania. Compositions and methods for treating cancer. WO2004100885. 2004."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)41006-4"},{"key":"cit0055","unstructured":"INSERM (Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale), Universit\u00e9 Paris Descartes, Sorbonne Universit\u00e9, Universit\u00e9 Paris Diderot \u2013 paris 7, Assistance Publique-H\u00f4pitaux de Paris (APHP), Universit\u00e9 Paris-Sud. Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers. WO2019175113. 2019."},{"key":"cit0056","unstructured":"INSERM (Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale) Assistance Publique-H\u00f4pitaux de Paris (APHP), Universit\u00e9 Paris Descartes, Universit\u00e9 Pierre et Marie Curie (Paris 6), Universit\u00e9 Paris Diderot \u2013 Paris 7 Universit\u00e9 Paris-Sud, Institut Gustave Roussy, Centre National de la recherche scientifique (CNRS). Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof. WO2015049365. 2015."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.10.026"},{"key":"cit0058","unstructured":"Dezima Pharma BV Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an ATP citrate lyase inhibitor \u2013 AMPK activator. WO2017023165. 2017."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M030528"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.310676"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.308963"},{"key":"cit0063","unstructured":"cited 2021 Dec 15. www.clinicaltrials.gov"},{"key":"cit0064","unstructured":"Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid. WO2019161307. 2019."},{"key":"cit0065","unstructured":"Suzhou Lixin Pharmaceutical Co. Ltd. Green preparation of bempedoic acid. CN113149829. 2021."},{"key":"cit0066","unstructured":"Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses. WO2004067489. 2004."},{"key":"cit0067","unstructured":"Shenzhen Targetrx Inc. Substituted pentadecanedioic acid compound and pharmaceutical composition and application thereof. CN110054562. 2019."},{"key":"cit0068","unstructured":"Memorial Sloan Kettering Cancer Center. Inhibition of Acetyl-CoA metabolism for treatment and prevention of immune system diseases and disorders. WO2018053233. 2018."},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.08.025"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.03.017"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.04.008"},{"key":"cit0072","author":"Artemis N","journal-title":"US20200157076"},{"key":"cit0073","unstructured":"Banyu Pharma Co. Ltd. ATP-citrate lyase inhibiting substances of BE-063437 type and method for producing the same. JP2001261682. 2001."},{"key":"cit0074","unstructured":"Univ. China Three Gorges CTGU. ACLY (ATP citrate lyase) inhibitor for broad-spectrum tumor cell proliferation resistance. CN109893523. 2019."},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1039\/C9CC00256A"},{"key":"cit0076","unstructured":"Univ. Fudan. Diterpenoid compound in fir and preparation method and application thereof in pharmacy. CN111548255. 2020."},{"key":"cit0077","unstructured":"Univ. Taizhou. Application of heptacodium miconioides extract in preparation of ATP citrate lyase inhibitor. CN112641819. 2021."},{"key":"cit0078","unstructured":"Univ. Taizhou. Use of natural chlorogenic acid derivative in preparation of ATP-citrate lyase (ACL) inhibitor. CN112957352. 2021."},{"key":"cit0079","unstructured":"Fudan University. Intermolecular adduct of different terpenes in pseudotsuga forrestii and preparation method and pharmaceutical application thereof. CN113402384. 2021."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202109082"},{"key":"cit0081","unstructured":"Taizhou University. Natural triterpene-iridoid glycoside dimer hybrid and its preparation and use in preparation of ACL inhibitor. CN113563409. 2021."},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)39488-7"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)39489-9"},{"key":"cit0084","unstructured":"Institute for Cancer Research d\/b\/a The Research Institute of Fox Chase Cancer Center. PI3K\/LYN-ACLY signaling inhibition. WO2020243063. 2020."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03910"},{"key":"cit0086","unstructured":"The Board of Trustees of the Leland Stanford Junior University. Methods of identifying MYC-driven and lipogenesis-dependent neoplasms and methods of treating the same. WO2018170316. 2018."},{"key":"cit0087","unstructured":"The Brigham and Women\u2019s Hospital, Inc. Methods and compositions for the treatment of inflammatory diseases. WO2019074891. 2019."},{"key":"cit0088","unstructured":"Merck Patent GMBH. Use of protein histidine phosphatase. WO02070676. 2002."},{"key":"cit0089","unstructured":"Ajinomoto Co., Inc. Medicinal composition for inhibiting the expression of ATP-citrate lyase and use thereof. WO03099332. 2003."},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700875"},{"key":"cit0091","unstructured":"Shanghai Inst. Biol. Sciences. Application of ACL on sieving drugs for preventing obesity-related metabolic disturbance diseases. CN101579351. 2008."},{"key":"cit0092","unstructured":"Beth Israel deaconess medical center. Micro-RNA and obesity. WO2019178410. 2019."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202100672"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.2479"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666141224125117"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2067478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:04:01Z","timestamp":1655384641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2067478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,3]]}},"alternative-id":["10.1080\/13543776.2022.2067478"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2067478","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}